Literature DB >> 15991280

Clinical significance of expression of apoptotic signal proteins in gastric carcinoma tissue.

Xin-Han Zhao1, Shan-Zhi Gu, Hong-Gang Tian, Ping Quan, Bo-Rong Pan.   

Abstract

AIM: To evaluate the expressions of apoptotic signal proteins FADD, TRADD, FasL, Fas, and NFkappaB in gastric carcinoma tissues and their clinical significance.
METHODS: Western blot immune trace method was adopted to detect the expressions of apoptotic signal proteins FADD, TRADD, FasL, Fas, and NFkappaB in 55 tissue specimens of gastric carcinoma.
RESULTS: Five apoptotic signal proteins had different expressions in the gastric carcinoma samples and their expressions were not correlated to age (P = 0.085). Expressions of the FADD, FasL, Fas, and NFkappaB proteins reduced with increase of the volume of tumor with the exception of increased expression the TRADD protein (64.7-71.1%, P = 0.031). With gradual increase of the malignancy of gastric carcinoma tissues, expressions of the FADD, FasL, and Fas proteins decreased (78.6-28.0%, P = 0.008; 78.6-65.9%, P = 0.071; 100.0-46.3%, P = 0.014), while expressions of the TRADD and NFkappaB proteins increased (42.9-78.1%, P = 0.063; 78.6-79.1%, P = 0.134). With gradual increase of serum CEA, expression of the FADD protein decreased (62.5-34.0%, P = 0.073), but expressions of the TRADD, FasL, Fas, and NFkappaB proteins increased (0.0-80.8%, P = 0.005; 62.5-70.2%, P = 0.093; 0.0-70.2%, P = 0.003; 62.5-80.9%, P = 0.075). When compared to the tissues of gastric carcinoma without metastasis, the positive rate of expressions of the FADD and FasL proteins increased, whereas expressions of the TRADD, FADD, and NFkappaB proteins decreased. There was no significant difference between them (P = 0.095).
CONCLUSION: Gastric carcinoma is endurable to Fas-related apoptosis and apoptotic signal proteins are differently expressed in gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15991280      PMCID: PMC4504883          DOI: 10.3748/wjg.v11.i25.3846

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Comparison of simple acid-ethanol precipitation with gel exclusion chromatography for measuring leptin binding in serum of normal subjects and cancer patients.

Authors:  Nigel B Jamieson; Donald C McMillan; Duncan J F Brown; A Michael Wallace
Journal:  Ann Clin Biochem       Date:  2003-03       Impact factor: 2.057

2.  Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1.

Authors:  Shigehito Nakashima; Yusuke Hiraku; Saeko Tada-Oikawa; Terutoshi Hishita; Esteban C Gabazza; Shigenori Tamaki; Ichiro Imoto; Yukihiko Adachi; Shosuke Kawanishi
Journal:  J Biochem       Date:  2003-09       Impact factor: 3.387

3.  The pro-apoptotic FAS-associated factor 1 is specifically reduced in human gastric carcinomas.

Authors:  Marina Bjørling-Poulsen; Gerhard Seitz; Barbara Guerra; Olaf-Georg Issinger
Journal:  Int J Oncol       Date:  2003-10       Impact factor: 5.650

4.  [Expression of Fas, FasL and IFN-gamma in gastric cancer].

Authors:  Zhaohui Li; Zhanmin Wang; Zhilun Zhao; Yong Zhang; Yang Ke
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2003-08

5.  Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines.

Authors:  Markus J Dechant; Jörg Fellenberg; Christian G Scheuerpflug; Volker Ewerbeck; Klaus-Michael Debatin
Journal:  Int J Cancer       Date:  2004-05-01       Impact factor: 7.396

6.  Evaluation of carcinoembryonic antigen mRNA in living, necrotic, and apoptotic gastric cancer cells by reverse transcriptase-polymerase chain reaction.

Authors:  Noriaki Kojima; Katsuyuki Kunieda; Koji Matsui; Hiroki Kato; Shigetoyo Saji
Journal:  Surg Today       Date:  2003       Impact factor: 2.549

7.  Significance of apoptosis induced by tumor necrosis factor-alpha and/or interferon-gamma against human gastric cancer cell lines and the role of the p53 gene.

Authors:  Takami Fukui; Kouji Matsui; Hiroki Kato; Hiroshi Takao; Yasuyuki Sugiyama; Katsuyuki Kunieda; Shigetoyo Saji
Journal:  Surg Today       Date:  2003       Impact factor: 2.549

8.  [Roles of ERK1/2 MAPK in vitamin E succinate-induced apoptosis in human gastric cancer SGC-7901 cells].

Authors:  Yan Zhao; Kun Wu; Yinghui Yu; Guichang Li
Journal:  Wei Sheng Yan Jiu       Date:  2003-11

9.  Long-term evaluation of mice model infected with Helicobacter pylori: focus on gastric pathology including gastric cancer.

Authors:  D H Kim; S W Kim; Y J Song; T Y Oh; S U Han; Y B Kim; H J Joo; Y K Cho; D Y Kim; S W Cho; M W Kim; J H Kim; K B Hahm
Journal:  Aliment Pharmacol Ther       Date:  2003-07       Impact factor: 8.171

10.  Regression of upper gastric cancer in mice by FHIT gene delivery.

Authors:  Hideshi Ishii; Nicola Zanesi; Andrea Vecchione; Francesco Trapasso; Sai Yendamuri; Manuela Sarti; Raffaele Baffa; Matthew J During; Kay Huebner; Louise Y Y Fong; Carlo M Croce
Journal:  FASEB J       Date:  2003-07-03       Impact factor: 5.191

View more
  3 in total

1.  Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.

Authors:  Qian Li; Jie Peng; Xin-Hua Li; Ting Liu; Qing-Chun Liang; Gui-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

2.  Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues.

Authors:  Yin Li; Da-Fu Xu; Dong Jiang; Jun Zhao; Jin-Feng Ge; Shi-Ying Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Expression of nuclear factor kappaB in human gastric carcinoma: relationship with I kappaB a and prognostic significance.

Authors:  Georgia Levidou; Penelope Korkolopoulou; Nikolaos Nikiteas; Nikolaos Tzanakis; Irene Thymara; Angelica A Saetta; Christos Tsigris; George Rallis; Konstantin Vlasis; Efstratios Patsouris
Journal:  Virchows Arch       Date:  2007-04-12       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.